Preclinical studies of oxaliplatin in combination chemotherapy;Études précliniques de l'oxaliplatine en polychimiothérapie

Bulletin du Cancer

Volumn 88, Issue SPEC. ISS., 2001, Pages

  Raymond, E ^a   Faivre, S ^a   Coudray, A M ^a   Louvet, C ^a   Gespach, C ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

5 fluoro uracile; Cisplatin; Combinations; Oxaliplatin; Paclitaxel; Synergy; Thymidylate synthase inhibitors; Topoisomerase I inhibitors

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CARBOPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX;

CANCER COMBINATION CHEMOTHERAPY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; ANIMAL; AREA UNDER THE CURVE; BIOLOGICAL MODEL; CELL CULTURE; COLORECTAL TUMOR; DRUG EFFECT; DRUG INTERACTION; DRUG SCREENING; MOUSE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CISPLATIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; MICE; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0034833117     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Ongoing and unsaid on oxaliplatin: The hope
2. Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatin
3. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer
4. Oxaliplatin: A review of preclinical and clinical studies
5. Oxaliplatin: Mechanism of action and antineoplastic activity
6. Oxaliplatine: Le premier DACH-platine en clinique
7. Oxaliplatin for the treatment of advanced colorectal cancer: Future directions
8. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (Folfox 3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
9. Oxaliplatin with high-dose leucovorin and 5-fluoro-uracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
10. Irinotecan: Les différents schémas d'administration, les recherches d'associations, l'expérience en phase I
11. Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)
12. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells
13. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin
14. Biotransformations of oxaliplatin in rat blood in vitro
15. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichlorocyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts
16. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts
17. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts
18. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells
19. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA
20. Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells
21. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers
22. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel
23. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
24. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model
25. Chemosensitivity screening in vitro of various cultured human cancer cell lines to a new platinum complex, L-OHP: Oxalato (trans 1-1,2-diaminocyclohexane) platinum II
26. Role of the DNA mismatch repair proteins in the recognition of plarinum DNA adducts
27. The role of DNA mismatch repair in platinum drug resistance
28. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
29. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin
30. Activity of oxaliplatin against human tumor colony-forming units
31. Transport of Cis-Pt and Cis-Pt analogs in sensitive and resistant murine leukemia cell lines
32. Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato platinum; LOHP) with CDDP on various cells: Correlation with intracellular accumulation
33. Intracellular glutathione and cytotoxicity of platinum complexes
34. Altered glutathione metabolism in oxaliplarin resistant ovarian carcinoma cells
35. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin
36. Toxic effect of two antitumoral agents derived from platinum, the cisplatin and the oxaliplatin on primary cultures of proximal tubular cells of the kidney in rabbits
37. The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells
38. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model
39. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin
40. Comparison of experimental electron microscopy study in hamster of 12 anthracyclines, mitoxantrone and 4 platinum complex cardioroxicity
41. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
42. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: Preclinical data
43. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer
44. Antitumor activity of UFT + folinic acid (FA) in combination with oxaliplatin (Ox) against human HT29 colon cancer xenografts in athymic nude mice
45. Potentiating action of 5-fluorouracil when used in combination with platinum compounds and cyclophosphamide in treatment of advanced L1210 leukemia
46. Experimental study of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia
47. Oxalato-platinum or L-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
48. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line
49. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin
50. In vivo evaluation of the irinotecan-oxaliplatin combination
51. Asymmetrically substituted ethylenediamine platinum (II) complexes as antitumor agents: Synthesis and structure-activity relationships
52. Comparison of an oxaliplatin-taxol versus carboplatin-taxol regimen in the treatment of the MV-522 human lung tumor xenograft
53. Evaluation of oxaliplatin-tirapazamine-taxol combinations in the MV-522 human lung carcinoma xenograft model
54. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells
55. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines
56. Antitumor activity of L-OHP in mice
57. Comparative studies of antitumor activities of oxalate-(trans-1-1,2-cyclohexane diamine) platinum II and cis-dichlorodiamino platinum (II)
58. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane) platinum (II): New experimental data
59. Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5FU), mitomycin C (MTC) or cyclophosphamide (CPM) in a model of peritoneal carcinomatosis induced by colon cancer cells in BD IX rats
60. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
61. A historical perspective on oxaliplatin: Rethinking the role of platinum compounds and learning from near misses